No analyst coverage available for this stock.
Saniona AB (publ) is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative treatments for rare diseases, with a strong focus on epilepsy and central nervous system disorders. Founded in 2011 and headquartered in Glostrup, Denmark, the company leverages over 20 years of pioneering ion channel research to advance a proprietary drug discovery engine comprising more than 20,000 molecules targeting specific ion channels. Key pipeline candidates include Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 trials for obesity; Tesomet, in Phase 2b for hypothalamic obesity and Prader-Willi syndrome; SAN711 in Phase 1 for rare neuropathic disorders; and SAN903 in preclinical stages for inflammatory, fibrotic, and hematological conditions. Saniona operates across Sweden, Denmark, Germany, the United Kingdom, and Mexico, employing 22 people under CEO Thomas Feldthus. In the financial markets, it plays a vital role in the biotechnology sector by addressing unmet needs in rare diseases through ion channel modulation, potentially delivering first-in-class therapies to patients globally.